Mevion Medical Systems Successfully Completes Growth Financing; Well Positioned for Global Expansion

LITTLETON, Mass.–(BUSINESS WIRE)–#cancercare–Mevion Medical Systems, Inc. announced the successful closing of a $150
million financing transaction led by YuanMing
and other private equity investors, including Henan Maisheng
Medical Technology Co., Ltd and supported by certain existing investors,
including HOPU Investments and China Everbright Limited. The transaction
provides growth capital, clears existing debt, and optimizes the
shareholder structure. Other details of the transaction were not

The transaction brings Mevion a strong group of new and existing
investors who collectively manage over $10 billion in assets, providing
a solid capital base and long-term growth capital. HYPERSCAN™
pencil beam scanning
already represents a breakthrough in proton
therapy due to innovative new technologies like the Adaptive Aperture™
proton MLC. This additional capital funding will be used to further
distance Mevion’s technological leadership in the proton therapy
industry, as well as expand manufacturing capability to meet the
increased interest in HYPERSCAN systems. Globally, a portion of the
funding will be used to support Mevion’s expansion of the business to
emerging markets.

With a mission to extend treatment options to patients around the globe,
Mevion is the market
in compact proton systems. The company is already
experiencing tremendous interest in the HYPERSCAN technology throughout
the United States and Europe and is now eager to bring this
revolutionary pencil beam technology solution to the Asia Pacific
market. The HYPERSCAN system is currently treating patients at MedStar
Georgetown University Hospital
in Washington, D.C. and is being
installed at two more centers, one NCI-Designated Cancer Center in the
US and the MAASTRO
in the Netherlands. Two additional centers are in the final
design phase and Mevion is in negotiation for additional units in Asia.

About Mevion Medical Systems®

Mevion Medical Systems, Inc. is a leading provider of proton therapy
systems for use in radiation treatment for cancer patients. Mevion is
based in Littleton, Massachusetts, with presence in Europe and China.
For more information, please visit

Follow Mevion on Twitter:

Connect with Mevion on LinkedIn:


Melanie Benton, 978-540-1551